GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm
PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) (“Gyre”) on behalf of the company’s investors.
The investigation seeks to determine whether Gyre and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.
Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 – 0750, by email at abell@kaskelalaw.com, or by filling out our online form at:
https://kaskelalaw.com/case/gyre-therapeutics/
ABOUT KASKELA LAW:
Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about the firm, including our recent monetary recoveries for investors, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 – 1740.
KASKELA LAW LLC
D. Seamus Kaskela, Esquire
Adrienne Bell, Esquire
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com
This communication may constitute attorney advertising in certain jurisdictions.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
